About the Participants
John W. Walsh
President and CEO, Alpha-1 Foundation
Mr. Walsh is the co-founder, President and CEO of the Alpha-1 Foundation. Under his leadership, the organization has invested more than $28 million to support Alpha1-antitrypsin research and programs at 50 institutions in North America and Europe. He is also co-founder and President of AlphaNet, Inc., a disease management services company providing comprehensive care for 2,500 individuals. Due to the support provided by the Foundation and AlphaNet, eight companies have drugs in development for Alpha-1.
Mr. Walsh was diagnosed with Alpha1-antitrypsin deficiency in 1989.
Steven D. Nathan, M.D.
Inova Fairfax Hospital
Dr. Nathan is the Director of the Advanced Lung Disease Program and the Medical Director of the Lung Transplant Program at Inova Fairfax Hospital. He is also an Affiliate Professor of Biomedical Sciences at George Mason University. He received his medical degree at the University of the Witwatersrand Medical School in Johannesburg, South Africa. He is board certified in Internal Medicine, Pulmonary Disease, and Critical Care Medicine. Dr. Nathan has been widely published in a number of peer-reviewed journals and publications, including Chest and the Journal of Heart and Lung Transplantation.
Robert D. Lefebvre
Vice President, General Manager, U.S. Commercial Operations, CSL Behring
Bob Lefebvre joined CSL Behring in 2006 as Vice President, General Manager, U.S. Commercial Operations. Prior to joining the company, he was Vice President, Global Marketing, MDS Pharma Services, a top five contract research organization. Previously, he was head of the Oncology/Virology Business Unit at Bristol-Myers Squibb. Bob also spent a number of years in sales and marketing management roles with Sandoz Canada.
Dennis Jackman
Senior Vice President, Public Affairs, CSL Behring
Dennis Jackman is responsible for optimizing impacts on CSL Behring’s ability to provide lifesaving therapies worldwide. Previously, he served as Executive Director of the Plasma Protein Therapeutics Association for North America, the industry group
for advocacy, quality standards and communications. He has held senior public affairs positions in the pharmaceutical and biotechnology industries since 1989. Previously, he was senior legislative aide to U.S. Senator Arlen Specter of Pennsylvania, focusing on pharmaceutical, trade and tax policy.
About CSL Behring
CSL Behring is a global leader in plasma protein biotherapeutics. Dedicated to saving lives and improving the quality of life for patients with rare diseases worldwide, the company provides safe and effective plasma-derived and recombinant products and offers patients a wide range of related services.
CSL Behring LLC
1020 First Avenue
P.O. Box 61501
King of Prussia, PA 19406-0901
Phone: 610 878 4000
Fax: 610 878 4009
www.cslbehring.com
Return to Top
Previous:
Whats Most Important? |